View in EDS

526PTrial design and rationale for OPAL, a phase 2, randomized, double-blind study of apitegromab in patients aged <2 years with spinal muscular atrophy.

Saved in:
Bibliographic Details
Title: 526PTrial design and rationale for OPAL, a phase 2, randomized, double-blind study of apitegromab in patients aged <2 years with spinal muscular atrophy.
Authors: Servais, L.1,2 (AUTHOR), Crawford, T.3 (AUTHOR), Capocelli, K.4 (AUTHOR), Yao, B.4 (AUTHOR), Tirucherai, G.4 (AUTHOR), Xu, Y.4 (AUTHOR), Zhao, G.4 (AUTHOR), Marantz, J.4 (AUTHOR), Darras, B.5 (AUTHOR)
Source: Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09608966
DOI:10.1016/j.nmd.2025.105615